Shares making the superb strikes after hours: RealReal, Tilray, and Myriad, CNBC


Julie Wainwright (C), CEO of The RealReal takes phase in the firm’s IPO at the Nasdaq MarketSite in Unique York, June 28, 2019.

Lucas Jackson | Reuters

Try the firms making headlines after the bell:

Shares of RealReal surged 12.7% in after-hours buying and selling after asserting a smaller-than-expected second quarter loss as revenue surged. The very finest consignment firm reported an adjusted second-quarter lack of 28 cents per portion on revenue of $71.0 million. Analysts had expected a loss per portion of 33 cents on revenue of $70.1 million, per Refinitiv. Both active merchants and orders increased 40% for the reason that second quarter of final 365 days, per the firm’s press release. Julie Wainwright, CEO and founding father of RealReal, acknowledged the firm drove marketing and marketing leverage and strategic initiatives in the second quarter.

Tilray dropped 7.2% after the hashish firm supplied a wider-than-expected second-quarter loss. The firm reported an adjusted loss per portion of 32 cents on revenue of $45.9 million. Analysts had expected a loss per portion of 25 cents on revenue of $41.1 million, per Refinitiv. Tilray reported increased working prices from bid initiatives.

Shares of Myriad Genetics plummeted 16% after the molecular diagnostic firm supplied disappointing second-quarter earnings. The firm reported fourth quarter adjusted earnings per portion of 41 cents on revenue of $215 million. Analysts had expected earnings per portion of 47 cents on revenue of $221 million. Ticket Capone, president and CEO of Myriad, acknowledged revenue missed expectations for the fourth quarter attributable to lower reimbursement for its expanded provider screening take a look at.

Adaptive Biotechnologies fell by better than 10% after the firm posted its first quarterly document since going public. The firm posted a loss per portion of $1.23, better than the shortcoming of $1.01 a portion a 365 days earlier. Adaptive also reported revenue of $22.1 million, above the $19.3 million consensus estimate from Refinitiv. CEO Chad Robins acknowledged the firm is progressing on “come-length of time product functions across our existence sciences analysis, clinical diagnostics, and drug discovery firms.”

Qualcomm named Ticket McLaughlin as its recent board chairman. McLaughlin previously served as chairman and CEO of Palo Alto Networks. He’s going to replace Jeff Henderson, who will remain on the board. The stock used to be little changed.


Please enter your comment!
Please enter your name here